Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iterum Therapeutics (ITRM) Equity Ratio (2017 - 2022)

Historic Equity Ratio for Iterum Therapeutics (ITRM) over the last 6 years, with Q3 2022 value amounting to 0.45.

  • Iterum Therapeutics' Equity Ratio fell 1463.87% to 0.45 in Q3 2022 from the same period last year, while for Sep 2022 it was 0.45, marking a year-over-year decrease of 1463.87%. This contributed to the annual value of 0.55 for FY2021, which is 13560.44% up from last year.
  • As of Q3 2022, Iterum Therapeutics' Equity Ratio stood at 0.45, which was down 1463.87% from 0.57 recorded in Q2 2022.
  • Iterum Therapeutics' Equity Ratio's 5-year high stood at 0.81 during Q2 2018, with a 5-year trough of 2.13 in Q3 2020.
  • In the last 5 years, Iterum Therapeutics' Equity Ratio had a median value of 0.45 in 2021 and averaged 0.03.
  • Per our database at Business Quant, Iterum Therapeutics' Equity Ratio crashed by 340146.74% in 2020 and then soared by 13560.44% in 2021.
  • Iterum Therapeutics' Equity Ratio (Quarter) stood at 0.73 in 2018, then crashed by 239.23% to 1.02 in 2019, then plummeted by 51.32% to 1.54 in 2020, then soared by 135.6% to 0.55 in 2021, then decreased by 17.14% to 0.45 in 2022.
  • Its last three reported values are 0.45 in Q3 2022, 0.57 for Q2 2022, and 0.58 during Q1 2022.